Compounds > Methyl 2-benzoylbenzoate
Page last updated: 2024-12-05

Methyl 2-benzoylbenzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyl 2-benzoylbenzoate: a photoinitiator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11816
CHEMBL ID3629239
CHEBI ID191129
SCHEMBL ID28000

Synonyms (47)

Synonym
AC-16418
methyl 2-(phenylcarbonyl)benzoate
STK731405
einecs 210-112-3
nsc 3797
ai3-00516
methyl 2-benzoylbenzoate
nsc3797
2-benzoylbenzoic acid, methyl ester
nsc-3797
o-(methoxycarbonyl)benzophenone
606-28-0
methyl o-benzoylbenzoate
benzoic acid, 2-benzoyl-, methyl ester
benzoic acid, o-benzoyl-, methyl ester
TIMTEC1_000331
methyl-2-benzoylbenzoate, 97%
NCGC00175229-01
inchi=1/c15h12o3/c1-18-15(17)13-10-6-5-9-12(13)14(16)11-7-3-2-4-8-11/h2-10h,1h
HMS1534P01
methyl benzophenone-2-carboxylate
benzophenone-2-carboxylic acid methyl ester
2-benzoylbenzoic acid methyl ester
B1231
bdbm50129069
chembl3629239 ,
BRD-K82275274-001-01-1
AKOS003827563
CHEBI:191129
o-benzoyl benzomethoxycarbonyl(obm)
methyl-2-benzoylbenzoate
FT-0632520
SCHEMBL28000
DTXSID2060549 ,
2-benzoyl benzoic acid methyl ester
o-benzoylbenzoic acid methyl ester
o-benzoyl benzoic acid, methyl ester
W-105240
benzoic acid, benzoyl-, methyl ester
mfcd00017187
Z19663893
AS-12023
2-benzoyl benzoic acid methyl ester;benzoic acid, 2-benzoyl-, methyl ester;methyl 2-benzoylbenzoate;methyl 2-(phenylcarbonyl)benzoate;benzoic acid, o-benzoyl-, methyl ester;2-benzoyl benzoic acid methyl ester benzoic acid, 2-benzoyl-, methyl ester methyl
2-benzoylbenzoic acid-methyl ester
CS-W010289
F87465
XUP7S9NT59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzophenonesAny aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaIC50 (µMol)3,000.00001.66004.38678.0000AID1254039
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1254039Inhibition of Pseudomonas aeruginosa 301-5473 metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) using nitrocefin as substrate preincubated for 5 mins followed by substrate addition measured every 17 secs for 20 mins by microplate reader2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.60 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index24.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzoic anhydride
2-benzoylbenzoic acid: structure in first source		2.1110
indolebutyric acid
indolebutyric acid: RN given refers to parent cpd. indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1.		2.1110indol-3-yl carboxylic acidauxin;
plant hormone;
plant metabolite
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		2.1110alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
2-methyl-4'-(methylthio)-2-morpholinopropiophenone
2-methyl-4'-(methylthio)-2-morpholinopropiophenone: a photo-initiator		2.1710
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.1110alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Infections, Pseudomonas
[description not available]		02.1110
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.1110